
    
      This study is a Phase 2a, parallel group, double blind, vehicle-controlled study of the
      safety and efficacy of ARQ-252 0.3% cream in combination with NB-UVB phototherapy treatment
      in subjects with non-segmental facial vitiligo.
    
  